ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ТРАНСПЛАНТАЦИИ ТРУПНОЙ ПЕЧЕНИ

Aim of the study was to evaluate patient and graft survival after liver transplantation (LT) and to determine if primary disease diagnosis, early graft dysfunction or other factors affect it. Furthermore, we analyzed the reasonsof short-term and long-term deaths or retransplantations.Materials and methods. 192 LTs from donors with brain death were performed from December 2004 until June 2014. Recipient age varied from 5 to 71 years. Most frequent diagnosis was liver cirrhosis (mainly due to hepatitis C), then hepatocellular carcinoma (HCC), liver graft dysfunction, etc.Results and discussion. 1-year patient survival is 89.5%, graft survival is 87.7%, 3-year –87% and 84.6%, respectively, and 5-year – 83.5% and 83.0%, respectively. Early mortality (in fi rst 30 days after transplantation) was 8%, long-term mortality – 5.9%. Primary non-function graft (PNF) was the reason of 66.7% early deaths. In the long term, infections and oncology were the reasons of death with the same frequency – 36.4%. Early graft dysfunction including primary non-function signifi cantly decreases short term survival (p = 0.0002). Nevertheless, in the majority of cases graft function improves and doesn’t affect survival. Donor factors play role in outcomes: early dysfunction is higher (40.6%) in extended criteria donor group than in standard donor group (р = 0.0431). PNF has the same trend – 8.5% and 0.0%, respectively, but without signifi cance (р =0.0835). 5-year survival is remarkably lower in HCC group 40.8% (p = 0.003) than in other groups.Conclusion: survival after liver transplantation in our Center is comparable with the results of the world’s centers.Цель данного исследования – изучить выживаемость больных и трансплантатов в зависимости от диагно-за первичного заболевания, наличия ранней дисфункции трансплантата, причины летальности на разныхсроках, проанализировать результаты ретрансплантаций.Материалы и методы. С декабря 2004 года по июнь 2014 года в ФНЦТИО было выполнено 192 трансплантации печени от доноров с диагнозом «смерть мозга» 186 реципиентам в возрасте от 5 лет до 71 года. В структуре показаний к трансплантации на первом месте по частоте находился цирроз печени, чаще всего в исходе гепатита С, затем гепатоцеллюлярная карцинома, дисфункция трансплантата печени и другие заболевания.Результаты и обсуждение. Однолетняя выживаемость реципиентов составляет 89,5%, трансплантатов – 87,7%, трехлетняя – 87 и 84,6%, пятилетняя – 83,5 и 83,0% соответственно. Периоперационная летальность составила 8%, отдаленная – 5,9%. Основной причиной смерти в раннем послеоперационном периоде являлись первично не функционирующие трансплантаты (ПНФТ) – 66,7% потерь, в отдаленном – одинаково часто (36,4% потерь) злокачественные новообразования и инфекции. Ранняя дисфункция трансплантата (РДТ), включая ПНФТ, статистически значимо снижает выживаемость в раннем послеоперационном периоде (p = 0,0002). Однако у большинства больных РДТ обратима и в этом случае в дальнейшем не влияет на выживаемость. При использовании трансплантата от стандартного донора частота РДТ была статистически значимо меньше – 21,2%, чем при расширении критериев – 40,6% (р = 0,0431), а частота ПНФТ составила 0,0 и 8,5%, соответственно (р = 0,0835). Пятилетняя выживаемость при трансплантации по поводу ГЦК значимо ниже, чем при наличии других показаний – 40,8% (p = 0,003).Заключение: выживаемость реципиентов после трансплантации печени в нашем центре на сроке до 10 лет сопоставима с результатами мировых регистров

Early liver allograft dysfunction: risk factors, clinical course and outcomes

Early liver allograft dysfunction (EAD) is associated with a high incidence of graft loss and patient mortality in the first 6 weeks after orthotopic liver transplantation (OLT).The aim of this retrospective single-center study is to identify the risk factors of EAD and to compare the short- and long-term results in EAD and non-EAD groups.Materials and methods. The results of 213 consecutive deceased donor liver transplantations performed between December 2004 and February 2015 were included in the analysis. Indications for OLT were non-viral liver cirrhosis in 52% of cases, viral hepatitis C or B in 34 %, hepatocellular carcinoma in 8 %; retransplantations were performed in 6% of cases due to previous liver graft dysfunction. EAD was defined by Olthoff criteria (Olthoff et al., 2010).Results. Overall incidence of EAD was 41.3%, including 5.6% of primary non-function grafts (PNF), i.e. irreversible EAD. No significant differences between EAD and non-EAD groups were seen either among donors in their age, gender, cause of death, bilirubin, plasma sodium level, aminotransferases aktivity, or among the recipients in their age, gender, body mass index, MELD. Retransplantation, donor time on mechanical ventilation in the intensive care unit for more than 2 days, highrisk donor category, transplant surgery duration more than 9.5 hours, and cold ischemia time (CIT) > 8 hours were independent significant risk factors of EAD in a multivariate model. A 42-day mortality rates were 18.2% in EAD group (mostly due to PNF without urgent retransplantanion in 9.1%), and 0% in non-EAD group. Long-term results in EAD group were also significantly poorer: 1-, 5-, and 10-year graft survival rates were 74%, 68%, and 64%, respectively, versus 96%, 90%, and 83% in non-EAD group, Log-rank p = 0.0001.Conclusion. EAD significantly (≈ 20%) decreases the short-term graft and patient survival rates. Meanwhile, a reversible EAD has no impact on long-term results. Despite the increased risk of EAD, the liver grafts from high-risk donors are suitable for transplantation. The most important and modifiable risk factor is CIT (optimal timeframe 6 - 8 h), especially when HTK solution is used. The risk of EAD / PNF dramatically increases in case of combined donor and recipient risk factors

LONG-TERM OUTCOMES OF DECEASED DONOR LIVER TRANSPLANTATION

Aim of the study was to evaluate patient and graft survival after liver transplantation (LT) and to determine if primary disease diagnosis, early graft dysfunction or other factors affect it. Furthermore, we analyzed the reasonsof short-term and long-term deaths or retransplantations.Materials and methods. 192 LTs from donors with brain death were performed from December 2004 until June 2014. Recipient age varied from 5 to 71 years. Most frequent diagnosis was liver cirrhosis (mainly due to hepatitis C), then hepatocellular carcinoma (HCC), liver graft dysfunction, etc.Results and discussion. 1-year patient survival is 89.5%, graft survival is 87.7%, 3-year –87% and 84.6%, respectively, and 5-year – 83.5% and 83.0%, respectively. Early mortality (in fi rst 30 days after transplantation) was 8%, long-term mortality – 5.9%. Primary non-function graft (PNF) was the reason of 66.7% early deaths. In the long term, infections and oncology were the reasons of death with the same frequency – 36.4%. Early graft dysfunction including primary non-function signifi cantly decreases short term survival (p = 0.0002). Nevertheless, in the majority of cases graft function improves and doesn’t affect survival. Donor factors play role in outcomes: early dysfunction is higher (40.6%) in extended criteria donor group than in standard donor group (р = 0.0431). PNF has the same trend – 8.5% and 0.0%, respectively, but without signifi cance (р =0.0835). 5-year survival is remarkably lower in HCC group 40.8% (p = 0.003) than in other groups.Conclusion: survival after liver transplantation in our Center is comparable with the results of the world’s centers

Liver transplantation in the Moscow Region: the regional project and its implementation

Rationale: Liver transplantation is the only curative treatment for diffuse end-stage liver disease and some liver neoplasms. The amount of these interventions in the Moscow Region is very low.Aim: To analyze the results of the first series of liver transplantations done in the Moscow Regional Research and Clinical Institute (MONIKI), to compare it with those done currently in Russia and worldwide, and to establish the optimal volume and trend of development for this new regional center.Materials and methods: More than 200 patients with liver cirrhosis, polycystosis and alveococcus invasion have been examined from May 2016 to August 2018; 70 of them were eligible for liver transplantation and were put on the waiting list. From October 2016 to July 2018, 29  liver transplantations from deceased donors (including 2  retransplantations) and one living related transplantation of the right lobe have been performed. Among the indications to the transplantation, the leading one was viral (HCV or HBV-related) cirrhosis. Four patients were diagnosed with hepatocellular carcinoma.Results: The waitlist mortality was 19%. Median waiting time was 5.5 [3; 9] (0 to 27) months. Until now, the results were followed till 22 months, with median follow-up of 7  [2; 13] months. The survival rate of the recipients was 96.4%, of the grafts 93.3%. In-patient mortality was 3.6%. Early allograft dysfunction was seen in 33%  of cases. Median length of the in-hospital stay was 22 [19; 25] days.Conclusion: The successful implementation of the liver transplant program at its initial stage demonstrates the results that meet current efficacy criteria. Achieved level of organ procurement from deceased donors in the Moscow Region could ensure at least 30  liver transplantations annually, with current facilities and a potential for further growth. An increase in the transplantation number would depend on the improvement of transplantation service facilities in MONIKI and on the stable financial support of the program. Finally, it would promote increased availability of this transplantation technology in the region, lower waitlist mortality and shorter waiting times